Antibody-drug conjugates or ADCs are a new class of highly potent biopharmaceutical drugs designed as a
targeted therapy for the treatment of people with cancer. ADCs are complex molecules composed of an
antibody (a whole mAb or an antibody fragment such as a
single-chain variable fragment [scFv]) linked, via a stable, chemical, linker with labile bonds, to a biological active
cytotoxic (anticancer) payload or drug. Antibody Drug Conjugates are examples of
bioconjugates and
immunoconjugates.